Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: What to Do About Missed CAB + RPV LA Injections?

Source: Key Decisions in HIV Care
Listen as Milena Murray, PharmD, MSc, BCIDP, AAHIVP, shares how to manage planned and unplanned missed CAB plus RPV LA injections according to the FDA label and pharmacokinetic modeling.
person default
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Released: October 13, 2021

In this episode, Milena Murray, PharmD, MSc, BCIDP, AAHIVP, explores recommendations and data to support the management of missed CAB plus RPV injections.

Listen as she gives her perspectives on:

  • Prescribing information recommendations for managing missed injections of CAB plus RPV
  • Pharmacokinetic modeling data to support management strategies for missed injections
  • Data from the ATLAS and FLAIR studies on missed injections and patient outcomes

Information on this Educational Activity

Faculty

Milena Murray, PharmD, MSc, BCIDP, AAHIVP

Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Pharmacy
Northwestern Memorial Hospital
Chicago, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Expert commentary on what long-acting ART means for people with HIV, from Dr Jean-Michel Molina and Clinical Care Options (CCO)

Jean-Michel Molina, MD, PhD Released: November 30, 2021

Commentary from Dr Karine Lacombe on the potential role of an investigational 2-drug regimen of lenacapavir plus islatravir, from Clinical Care Options (CCO)

Karine Lacombe, MD, PhD Released: November 30, 2021

Clinical Care Options (CCO) expert analysis of new data from EACS 2021, provided by expert HIV faculty

person default Tristan J. Barber, MA, MD, FRCP Released: November 30, 2021

One patient’s journey from HIV diagnosis to undetectable while trying to lose weight, from Clinical Care Options (CCO)

person default Anonymous Patient Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue